Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Cash from Operations (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Cash from Operations for 4 consecutive years, with 9787000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations fell 145.35% year-over-year to 9787000.0, compared with a TTM value of 69714000.0 through Sep 2025, up 26.35%, and an annual FY2024 reading of 68717000.0, up 64.39% over the prior year.
  • Cash from Operations was 9787000.0 for Q3 2025 at Atara Biotherapeutics, down from 7318000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 3989000.0 in Q3 2024 and bottomed at 84529000.0 in Q1 2022.
  • Average Cash from Operations over 4 years is 38491133.33, with a median of 38429000.0 recorded in 2023.
  • The sharpest move saw Cash from Operations skyrocketed 92.23% in 2024, then tumbled 145.35% in 2025.
  • Year by year, Cash from Operations stood at 56880000.0 in 2022, then rose by 11.38% to 50406000.0 in 2023, then skyrocketed by 51.45% to 24471000.0 in 2024, then skyrocketed by 60.01% to 9787000.0 in 2025.
  • Business Quant data shows Cash from Operations for ATRA at 9787000.0 in Q3 2025, 7318000.0 in Q2 2025, and 28138000.0 in Q1 2025.